Workflow
Antengene Corporation (06996) Earnings Call Presentation
ANTENGENEANTENGENE(HK:06996)2025-07-02 07:28

Company Overview - Antengene is focused on bringing transformative medicines to patients globally, with commercialization in 6 APAC markets and 9 clinical-stage assets[12, 13] - The company raised US$21 million in Series A, US$120 million in Series B, US$97 million in Series C, and US$367 million in its Hong Kong IPO[21] - As of June 30, 2023, Antengene had RMB 1,322 million in cash and bank balances[21, 225] Pipeline Highlights - For CPI-naïve relapsed/metastatic cervical cancer, ATG-008 (Onatasertib) showed an ORR of 53.3% (16/30) and mPFS of 8.41 months[15] - In CPI-treated relapsed/metastatic cervical cancer, ATG-008 (Onatasertib) showed an ORR of 29.4% (5/17)[15] - In treatment-naïve myelofibrosis patients, Selinexor 60 mg + Ruxolitinib achieved SVR35 of 83.3% (10/12) at week 12 and 91.7% (11/12) at week 24 in efficacy evaluable patients[30] - In TP53 Wild-type Endometrial Cancer Patients, Selinexor monotherapy showed mPFS of 27.4 months compared to 5.2 months for placebo, with HR: 0.42[32] Commercial Performance & Partnerships - XPOVIO® achieved RMB 72.0 million in revenue in 2023 1H, a 33.5% increase compared to RMB 54.0 million in 2022 1H[15] - Antengene entered into a commercialization partnership with Hansoh Pharma in the Mainland of China on August 11th[15] - XPOVIO® has covered 130 DTP pharmacies across the Mainland of China and attained 46 urban-customized commercial health insurance listings (Huiminbao) covering over 55 million people[202] - From commercial launch in May 2022 to June 30th, 2023, XPOVIO® accumulated revenue of RMB 222.1 Million[202]